Clinical Trial Detail

NCT ID NCT03999749
Title A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors NYU Langone Health
Indications

melanoma

Therapies

Nivolumab

Ipilimumab + Nivolumab + Tocilizumab

Age Groups: senior adult

No variant requirements are available.